Pacific Biosciences of California (NASDAQ:PACB) Shares Up 3.9%
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 3.9%
Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) shot up 3.9% during trading on Wednesday . The company traded as high as $6.08 and last traded at $6.06. 42,602 shares were traded during mid-day trading, a decline of 99% from the average session volume of 5,826,232 shares. The stock had previously closed at $5.83.
加州太平洋生物科學公司(納斯達克代碼:PACB-GET評級)的股價在週三的交易中飆升3.9%。該公司股價一度高達6.08美元,最新報6.06美元。午盤成交量為42,602股,較5,826,232股的平均成交量下降99%。該股此前收盤價為5.83美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of brokerages have recently commented on PACB. Piper Sandler lowered their price target on Pacific Biosciences of California from $7.50 to $6.00 in a research note on Sunday, August 21st. Canaccord Genuity Group lowered their target price on Pacific Biosciences of California from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, August 5th. Finally, Cowen lowered their target price on Pacific Biosciences of California to $8.00 in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $22.00.
多家券商近期紛紛對PACB發表評論。派珀·桑德勒在8月21日週日的一份研究報告中將他們對加州太平洋生物科學公司的目標價從7.50美元下調至6.00美元。Cancord Genuity Group在8月5日(星期五)的一份研究報告中將其對加州太平洋生物科學公司的目標價從17.00美元下調至14.00美元,並對該公司設定了“買入”評級。最後,考恩在8月9日星期二的一份研究報告中將他們對加州太平洋生物科學公司的目標價下調至8.00美元。一位分析師對該股的評級為賣出,一位分析師給出了持有評級,四位分析師給出了該公司的買入評級。根據MarketBeat.com的數據,該公司目前的平均評級為“中等買入”,平均目標價為22.00美元。
Pacific Biosciences of California Price Performance
加州價格表現的太平洋生物科學
The company has a quick ratio of 11.07, a current ratio of 11.50 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average price of $5.88 and a 200 day moving average price of $6.45.
該公司的速動比率為11.07,流動比率為11.50,債務權益比為1.31。該公司的50日移動平均價為5.88美元,200日移動平均價為6.45美元。
Insider Activity
內幕活動
In related news, insider Christian O. Henry sold 91,307 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $5.78, for a total value of $527,754.46. Following the sale, the insider now owns 688,551 shares in the company, valued at approximately $3,979,824.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.40% of the stock is currently owned by insiders.
在相關新聞中,內部人士克里斯蒂安·O·亨利在9月15日(星期四)的一次交易中出售了91,307股該股。這隻股票的平均售價為5.78美元,總價值為527,754.46美元。出售後,這位內部人士現在擁有該公司688,551股,價值約3979,824.78美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過此超鏈接。目前該公司1.40%的股份由內部人士持有。
Institutional Investors Weigh In On Pacific Biosciences of California
機構投資者看好加州太平洋生物科學公司
Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its position in Pacific Biosciences of California by 190.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 8,438,572 shares of the biotechnology company's stock worth $37,299,000 after buying an additional 5,533,953 shares during the period. Price T Rowe Associates Inc. MD increased its position in Pacific Biosciences of California by 68.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 10,284,090 shares of the biotechnology company's stock worth $45,456,000 after buying an additional 4,179,997 shares during the period. Bellevue Group AG increased its position in Pacific Biosciences of California by 214.3% during the 1st quarter. Bellevue Group AG now owns 4,881,752 shares of the biotechnology company's stock worth $44,424,000 after buying an additional 3,328,729 shares during the period. Invesco Ltd. increased its position in Pacific Biosciences of California by 3,355.2% during the 4th quarter. Invesco Ltd. now owns 3,195,790 shares of the biotechnology company's stock worth $65,386,000 after buying an additional 3,103,297 shares during the period. Finally, Blue Water Life Science Advisors LP bought a new position in Pacific Biosciences of California during the 1st quarter worth $24,206,000.
大型投資者最近增持或減持了該公司的股份。第二季度,高盛公司將其在加州太平洋生物科學公司的持有量增加了190.5%。高盛股份有限公司目前持有這家生物技術公司8,438,572股股票,價值37,299,000美元,在此期間又購買了5,533,953股。Price T Rowe Associates Inc.MD在第二季度將其在加利福尼亞州太平洋生物科學公司的頭寸增加了68.5%。Price T Rowe Associates Inc.MD現在持有這家生物技術公司10,284,090股股票,價值45,456,000美元,在此期間又購買了4,179,997股。貝爾維尤集團在第一季度將其在加州太平洋生物科學公司的地位增加了214.3%。貝爾維尤集團(Bellevue Group AG)目前持有這家生物技術公司4881,752股股票,價值44,424,000美元,在此期間又購買了3,328,729股。第四季度,景順公司在加利福尼亞州太平洋生物科學公司的股份增加了3,355.2%。景順公司目前持有這家生物技術公司3,195,790股股票,價值65,386,000美元,在此期間又購買了3,103,297股。最後,Blue Water Life Science Advisors LP在第一季度收購了加州太平洋生物科學公司的一個新頭寸,價值24,206,000美元。
About Pacific Biosciences of California
關於加州的太平洋生物科學
(Get Rating)
(獲取評級)
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
加州太平洋生物科學公司設計、開發和製造測序系統,以解決基因複雜的問題。該公司提供進行、監測和分析生化測序反應的PacBio系統;消耗品,包括單分子實時(SMRT)細胞;以及為特定工作流程設計的各種試劑盒,如將DNA轉化為SMRTbell雙鏈DNA文庫格式的模板製備試劑盒,包括連接酶、緩衝液和核酸外切酶等分子生物學試劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免費獲取StockNews.com關於加州太平洋生物科學的研究報告(PACB)
- 這些機構持有達頓餐飲國際公司的股份
- 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎?
- 住房建設的黃金時代已經結束了嗎?
- 這三大股利支付者也擁有強勁的價格增長
- 天然氣價格繼續回升,這些股票應該會受益
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《加州日報》太平洋生物科學的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對加利福尼亞州太平洋生物科學公司和相關公司的最新新聞和分析師評級的每日簡要摘要。